UCB Spotlights Bimekizumab And Other Later-Stage R&D Projects

 
• By John Davis

Belgium-headquartered UCB has a group of antibody-based products in mid to late-stage clinical studies which will be competing in the dermatology/immune disorders marketplace in the next few years. 

Pipeline
UCB is investing in its R&D pipeline • Source: Shutterstock.

More from Immunological

More from Therapy Areas